Private Equity

A company named for mining is betting big on Bali's luxury villa market. But with a tiny market cap and an unknown builder, is it a brilliant pivot or a risky gamble?

A new US-DRC partnership aims to create an ethical cobalt supply chain, challenging Chinese dominance and revitalizing American mineral processing.

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

A CEO's personal battle with prostate cancer inspired a community golf tournament that is now on the verge of raising $1 million for critical research.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

After devastating storms, The Ritz-Carlton Oʻahu, Turtle Bay, calls for respectful tourism to help rebuild the North Shore's economy and community.

Slate Aviation adds Westhampton and Nantucket routes, tapping into a booming market for per-seat private flights that blend luxury with convenience.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

Despite a historic tariff shock, new data shows middle market dealmaking adapted and thrived, with private equity rewriting its playbook for a new era.

With a new billion-dollar brand builder as CFO and $1.5B in backing, Montera is poised to challenge leaders in the booming AI infrastructure market.

As the ready-to-drink market surges, a new high-capacity Miami facility offers brands a lifeline for scaling production and navigating complex regulations.

GO Residential REIT declares its April dividend, backed by a robust NYC luxury rental market. But what do cross-border tax rules mean for investors?

In a tough fundraising climate, Topspin Consumer Partners' oversubscribed Fund III shows investors are betting big on founder-led brands and operational expertise.

Lobbying spending shattered records at $5.3 billion in 2025, driven by battles over trade, taxes, AI, and a surge in Trump-aligned influence firms.

Philip Morris International's upcoming Q1 2026 earnings will be a crucial test of its pivot from cigarettes, with all eyes on ZYN's growth and regulatory hurdles.

A new climate-tech firm is now selling verified carbon removal credits from a unique process that also creates clean energy, a rare feat in today's market.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

Vince Holding Corp. posts a full-year profit, shaking off retail headwinds with a powerful direct-to-consumer strategy, despite a hit from Saks' turmoil.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.